

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**SEVENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM APRIL 1, 2020 THROUGH APRIL 30, 2020**

Name of Applicant:

FTI Consulting, Inc.

Authorized to provide Professional Services
to:

Ad Hoc Committee of Governmental and
Other Contingent Litigation Claimants

Date of Order Approving Debtors' Payment
of Fees and Expenses of Applicant:

December 2, 2019 [ECF No. 553]

Period for which compensation and
reimbursement is sought:

April 1, 2020 through April 30,
2020

Monthly Fees Incurred:

\$428,303.00

1 The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$1,732.28

Total Fees and Expenses Due: \$430,035.28

This is a: X monthly _____ interim _____ final application

PRIOR APPLICATIONS:

Docked No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$623,033.20	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$662,060.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$641,629.20	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$619,729.60	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$492,071.20	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$449,490.80	\$67.08

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529]

and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee's Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the "**Orders**"). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from April 1, 2020 through and including April 30, 2020 (the "**Seventh Fee Period**") amount to:

Professional Fees	\$428,303.00
Expenses	<u>1,732.28</u>
TOTAL	<u>\$430,035.28</u>

2. In accordance with the Orders, FTI has separately recorded its fees in connection with or relating to the allocation of value among the Debtors' creditors (the "**Allocation Fees**") and has not, to the best of its knowledge, included Allocation Fees in this Fee Statement. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$342,642.40
Expenses at 100%	<u>1,732.28</u>
TOTAL	<u>\$344,374.68</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Seventh Fee Period are set forth on the schedule annexed hereto as **Exhibit "A."**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Seventh Fee Period is set forth on the schedule annexed hereto as **Exhibit "B."**

5. Detailed time entry by task code during the Seventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Seventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**
7. Detailed breakdown of the expenses incurred during the Seventh Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Seventh Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than June 24, 2020 (the “Objection Deadline”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “Objection”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
June 10, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Professional	Position	Specialty	Billing Rate¹	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Dir	Restructuring	\$ 1,085	76.7	\$ 83,219.50
Greenblatt, Matthew	Sr Managing Dir	Forensics	985	2.1	2,068.50
Joffe, Steven	Sr Managing Dir	Tax	1,125	5.2	5,850.00
Simms, Steven	Sr Managing Dir	Restructuring	1,295	4.6	5,957.00
Butterfield, Linda	Senior Director	Forensics	665	13.6	9,044.00
Knechtel, Karl	Senior Director	Restructuring	845	22.2	18,759.00
Suric, Emil ²	Senior Director	Healthcare	820	3.8	3,116.00
Bromberg, Brian	Director	Restructuring	815	217.3	177,099.50
Harsha, Adam	Director	Forensics	500	10.4	5,200.00
Kim, Ye Darm ²	Sr Consultant	Restructuring	560	119.6	66,976.00
Tirabassi, Kathryn ²	Sr Consultant	Restructuring	560	12.5	7,000.00
Causton, Daniel	Consultant	Forensics	345	5.0	1,725.00
Kurtz, Emma	Consultant	Restructuring	415	101.9	42,288.50
GRAND TOTAL			594.9		\$ 428,303.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

2. Select individuals were promoted as of April 1, 2020 resulting in rate increases accordingly.

EXHIBIT B**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF HOURS BY TASK****FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	33.0	\$ 23,352.50
2	Cash & Liquidity Analysis	2.0	1,855.00
7	Analysis of Domestic Business Plan	16.8	11,211.00
10	Analysis of Tax Issues	21.3	18,134.00
11	Prepare for and Attend Court Hearings	1.0	815.00
13	Analysis of Other Miscellaneous Motions	131.5	96,500.00
18	Review of Historical Transactions	4.3	4,058.00
19	Case Management	6.6	5,330.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	6.3	4,755.00
24	Preparation of Fee Application	12.5	7,000.00
26	Analysis of Insurance Programs	10.1	7,546.00
28	Review of IAC Business Plan	349.5	247,746.50
GRAND TOTAL¹		594.9	\$ 428,303.00

1. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020**

Task Category	Date	Professional	Hours	Activity
1	4/1/2020	Diaz, Matthew	1.6	Review of the recent financial results in preparation for the Committee call.
1	4/1/2020	Knechtel, Karl	1.3	Update summary re: January 2020 flash report.
1	4/1/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/2/2020	Knechtel, Karl	1.1	Incorporate updates to summary re: January 2020 flash report.
1	4/2/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/3/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/6/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/9/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/14/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/15/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/16/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/22/2020	Kim, Ye Darm	1.3	Review Debtors' February monthly operating report.
1	4/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/23/2020	Bromberg, Brian	2.3	Prepare reporting summary.
1	4/23/2020	Bromberg, Brian	1.4	Review the February monthly operating report.
1	4/23/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/24/2020	Kim, Ye Darm	1.1	Draft diligence questions re: February monthly operating report.
1	4/24/2020	Kim, Ye Darm	1.8	Draft summary of February monthly operating report.
1	4/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/27/2020	Bromberg, Brian	1.2	Review comments on February financial update.
1	4/27/2020	Bromberg, Brian	0.9	Finalize questions list to send to the Debtors' advisors.
1	4/27/2020	Bromberg, Brian	1.9	Revise summary of February update.
1	4/27/2020	Bromberg, Brian	1.8	Revise questions on financial update.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
1	4/27/2020	Bromberg, Brian	2.4	Review comments on February financial update.
1	4/27/2020	Diaz, Matthew	0.5	Review the donation press release.
1	4/27/2020	Diaz, Matthew	1.4	Review the February results.
1	4/27/2020	Kim, Ye Darm	0.5	Review February YTD operating results.
1	4/27/2020	Kim, Ye Darm	0.9	Prepare revisions to February monthly operating report summary.
1	4/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/29/2020	Kim, Ye Darm	1.3	Update February monthly operating report summary.
1	4/29/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	4/30/2020	Bromberg, Brian	1.3	Finalize summary of February financial update.
1 Total			33.0	
2	4/22/2020	Diaz, Matthew	0.3	Review the updated cash analysis.
2	4/22/2020	Kim, Ye Darm	0.6	Review Debtors' latest cash report.
2	4/23/2020	Diaz, Matthew	1.1	Review the February cash update.
2 Total			2.0	
7	4/13/2020	Bromberg, Brian	1.2	Finalize domestic business plan requests.
7	4/13/2020	Kim, Ye Darm	0.2	Prepare updated requests re: domestic business plan forecasts.
7	4/15/2020	Kim, Ye Darm	0.6	Review Debtors' document productions to identify documents responsive to requests.
7	4/23/2020	Bromberg, Brian	0.2	Follow up with Debtors on diligence items.
7	4/24/2020	Kim, Ye Darm	1.4	Review source documents for domestic business plan summary.
7	4/27/2020	Bromberg, Brian	0.5	Participate in call with the Debtors' advisors re: updated business plan.
7	4/27/2020	Diaz, Matthew	0.7	Review the PHI initiatives in relation to the Debtors' business plan.
7	4/27/2020	Diaz, Matthew	0.5	Participate in call with the Debtors' advisors re: updated business plan.
7	4/27/2020	Kim, Ye Darm	0.5	Participate in call with the Debtors' advisors re: updated business plan.
7	4/27/2020	Kim, Ye Darm	0.4	Review dataroom for productions re: forecasts.
7	4/29/2020	Kim, Ye Darm	2.9	Analyze Debtors' revised domestic business plan.
7	4/30/2020	Bromberg, Brian	2.7	Review April updated business plan.
7	4/30/2020	Kim, Ye Darm	3.4	Prepare analysis re: updated domestic business plan.
7	4/30/2020	Kim, Ye Darm	1.6	Prepare summary re: updated domestic business plan.
7 Total			16.8	
10	4/1/2020	Joffe, Steven	1.0	Participate on call with tax advisors to discuss outstanding tax issues.
10	4/14/2020	Bromberg, Brian	0.8	Review tax outstanding items.
10	4/17/2020	Bromberg, Brian	0.5	Participate on call with KPMG tax advisors re: IAC tax update.
10	4/17/2020	Bromberg, Brian	1.9	Review tax update summary.
10	4/17/2020	Bromberg, Brian	2.7	Incorporate updates to tax summaries.
10	4/17/2020	Kurtz, Emma	0.5	Participate on call with KPMG tax advisors re: IAC tax update.
10	4/23/2020	Joffe, Steven	1.3	Participate on call with tax advisors to discuss outstanding tax issues.
10	4/28/2020	Bromberg, Brian	1.8	Review CARES Act tax refund impact.
10	4/28/2020	Bromberg, Brian	1.5	Review summary re: CARES Act tax refund.
10	4/28/2020	Diaz, Matthew	0.6	Review the domestic NOL tax analysis.
10	4/28/2020	Joffe, Steven	1.5	Participate on call with tax advisors to discuss next steps re: tax issues.
10	4/28/2020	Kim, Ye Darm	3.4	Incorporate updates to summary re: CARES Act NOL refund.
10	4/29/2020	Kim, Ye Darm	0.9	Incorporate further updates to summary re: CARES Act NOL refund.
10	4/30/2020	Bromberg, Brian	0.4	(Partial) Participate in tax update call.
10	4/30/2020	Diaz, Matthew	0.5	Review the updated NOL domestic tax analysis.
10	4/30/2020	Diaz, Matthew	0.6	(Partial) Participate in tax update call.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
10	4/30/2020	Joffe, Steven	1.4	Participate in tax update call.
10 Total			21.3	
11	4/22/2020	Bromberg, Brian	1.0	Attend (telephonically) fee hearing.
11 Total			1.0	
13	4/2/2020	Diaz, Matthew	0.7	Review the OTC Naloxone motion.
13	4/3/2020	Diaz, Matthew	1.6	Review the OTC Naloxone agreement and related questions.
13	4/3/2020	Kim, Ye Darm	1.3	Update draft of funding agreement diligence questions.
13	4/3/2020	Kim, Ye Darm	2.1	Prepare summary re: OTC Naloxone funding agreement diligence.
13	4/3/2020	Kim, Ye Darm	1.3	Draft summary of Brenkus report re: Funding Agreement diligence.
13	4/3/2020	Kim, Ye Darm	1.7	Review Brenkus report on OTC Naloxone.
13	4/3/2020	Knechtel, Karl	1.2	Review questions from counsel re: HRT motion.
13	4/3/2020	Knechtel, Karl	1.4	Review updated Brenkus report re: OTC Naloxone.
13	4/3/2020	Knechtel, Karl	1.8	Review updated request list re: HRT motion.
13	4/6/2020	Butterfield, Linda	2.1	Conduct research re: HRT motion.
13	4/6/2020	Diaz, Matthew	1.9	Review the Naloxone OTC agreements.
13	4/6/2020	Diaz, Matthew	0.9	Participate in a call with the Debtors on the Naloxone OTC agreement.
13	4/6/2020	Diaz, Matthew	1.6	Participate in meeting with the Debtors' special committee re: HRT diligence.
13	4/6/2020	Kim, Ye Darm	0.9	Participate in a call with the Debtors on the Naloxone OTC agreement.
13	4/6/2020	Kim, Ye Darm	1.4	Incorporate updates to summary re: OTC Naloxone diligence.
13	4/6/2020	Kim, Ye Darm	2.8	Prepare updated draft of OTC Naloxone diligence summary.
13	4/6/2020	Kim, Ye Darm	1.6	Participate in meeting with the Debtors' special committee re: HRT diligence.
13	4/6/2020	Knechtel, Karl	3.1	Incorporate updates to analysis re: HRT and OTC Naloxone.
13	4/6/2020	Knechtel, Karl	0.9	Participate in a call with the Debtors on the Naloxone OTC agreement.
13	4/6/2020	Simms, Steven	1.4	Review analysis prepared by the team re: HRT motion.
13	4/6/2020	Suric, Emil	1.7	Prepare analysis re: OTC Naloxone.
13	4/7/2020	Butterfield, Linda	3.4	Conduct additional research re: HRT motion.
13	4/7/2020	Diaz, Matthew	0.7	Participate on call with Committee professionals re: OTC Naloxone motion.
13	4/7/2020	Diaz, Matthew	1.9	Review the updated OTC Naloxone analysis.
13	4/7/2020	Diaz, Matthew	1.5	Review the motion and supporting documents in connection with the OTC Naloxone proposal.
13	4/7/2020	Kim, Ye Darm	1.1	Prepare analysis re: OTC Naloxone Funding Agreement.
13	4/7/2020	Kim, Ye Darm	0.9	Prepare updated draft summary re: OTC Naloxone funding agreement diligence.
13	4/7/2020	Kim, Ye Darm	0.7	Participate on call with Committee professionals re: OTC Naloxone motion.
13	4/7/2020	Kim, Ye Darm	1.3	Incorporate updates to summary re: Funding Agreement diligence.
13	4/7/2020	Kim, Ye Darm	1.3	Prepare analysis re: OTC Naloxone.
13	4/7/2020	Knechtel, Karl	2.7	Review analysis re: HRT and OTC Naloxone.
13	4/7/2020	Knechtel, Karl	2.1	Prepare detailed comments re: OTC Naloxone and HRT analysis.
13	4/8/2020	Bromberg, Brian	1.1	Participate in diligence subcommittee call re: Naloxone motion.
13	4/8/2020	Butterfield, Linda	3.3	Conduct further research re: HRT motion.
13	4/8/2020	Diaz, Matthew	1.6	Finalize the HRT summary.
13	4/8/2020	Diaz, Matthew	0.9	Review materials in preparation for the subcommittee call on OTC Naloxone.
13	4/8/2020	Diaz, Matthew	1.1	Participate in diligence subcommittee call re: Naloxone motion.
13	4/8/2020	Kim, Ye Darm	1.4	Incorporate updates to analysis re: OTC Naloxone.
13	4/8/2020	Kim, Ye Darm	1.1	Participate in diligence subcommittee call re: Naloxone motion.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
13	4/8/2020	Kim, Ye Darm	0.6	Review UCC preliminary findings re: HRT diligence.
13	4/8/2020	Kim, Ye Darm	1.1	Prepare analysis re: OTC Naloxone.
13	4/8/2020	Knechtel, Karl	1.1	Participate in diligence subcommittee call re: Naloxone motion.
13	4/8/2020	Simms, Steven	0.7	Review outstanding HRT diligence items.
13	4/9/2020	Butterfield, Linda	1.8	Prepare analysis re: HRT motion.
13	4/9/2020	Diaz, Matthew	0.7	Review the updated HRT analysis.
13	4/9/2020	Harsha, Adam	2.4	Prepare analysis re: HRT motion.
13	4/9/2020	Kim, Ye Darm	0.6	Correspond with counsel re: access to OTC Naloxone productions.
13	4/10/2020	Bromberg, Brian	1.3	Review UCC and NCSG response to OTC Naloxone motion.
13	4/10/2020	Bromberg, Brian	2.7	Prepare summary re: OTC Naloxone.
13	4/10/2020	Bromberg, Brian	1.0	Participate in call with the Debtors re: OTC Naloxone questions.
13	4/10/2020	Butterfield, Linda	3.0	Prepare summary re: HRT analysis.
13	4/10/2020	Causton, Daniel	3.0	Conduct research re: HRT motion.
13	4/10/2020	Diaz, Matthew	1.6	Review materials in preparation for HRT call.
13	4/10/2020	Diaz, Matthew	1.0	Participate in call with the Debtors re: OTC Naloxone questions.
13	4/10/2020	Harsha, Adam	2.9	Conduct research re: HRT motion.
13	4/10/2020	Harsha, Adam	2.4	Prepare analysis re: HRT motion.
13	4/10/2020	Kim, Ye Darm	0.9	Prepare diligence request list re: OTC Naloxone Funding Agreement.
13	4/10/2020	Kim, Ye Darm	1.0	Participate in call with the Debtors re: OTC Naloxone questions.
13	4/10/2020	Kim, Ye Darm	1.8	Review NCSG draft statement re: funding motion and identify sources.
13	4/10/2020	Kim, Ye Darm	2.1	Prepare summary re: OTC Naloxone update.
13	4/10/2020	Knechtel, Karl	1.0	Participate in call with the Debtors re: OTC Naloxone questions.
13	4/11/2020	Bromberg, Brian	2.0	Review summary re: OTC Naloxone update.
13	4/11/2020	Diaz, Matthew	0.5	Review the updated due diligence list re: HRT motion.
13	4/11/2020	Kim, Ye Darm	1.3	Incorporate updates to summary re: OTC Naloxone update.
13	4/13/2020	Causton, Daniel	2.0	Conduct further research re: HRT motion.
13	4/13/2020	Diaz, Matthew	0.7	Participate on call with the Committee to discuss the HRT analysis.
13	4/13/2020	Diaz, Matthew	0.6	Participate in a call with the UCC and the non-consenting states to discuss the HRT motion.
13	4/13/2020	Harsha, Adam	2.7	Incorporate updates to analysis re: HRT motion.
13	4/13/2020	Kim, Ye Darm	0.6	Prepare updated OTC Naloxone Funding Agreement diligence request list.
13	4/13/2020	Kim, Ye Darm	2.4	Continue to prepare analysis re: HRT diligence.
13	4/13/2020	Kim, Ye Darm	2.6	Prepare analysis re: HRT diligence.
13	4/14/2020	Diaz, Matthew	0.8	Review the updated HRT analysis.
13	4/15/2020	Kim, Ye Darm	0.4	Update HRT diligence request list.
13	4/15/2020	Kim, Ye Darm	3.4	Prepare additional analysis re: HRT motion.
13	4/17/2020	Diaz, Matthew	0.6	Review the updated HRT analysis.
13	4/20/2020	Diaz, Matthew	0.6	Finalize list of follow up questions on the HRT motion.
13	4/20/2020	Diaz, Matthew	0.7	Participate in a call with Kramer to discuss the discovery and related review process.
13	4/20/2020	Kim, Ye Darm	1.6	Incorporate updates to analysis re: HRT motion.
13	4/20/2020	Kim, Ye Darm	0.7	Participate in a call with Kramer to discuss the discovery and related review process.
13	4/20/2020	Kim, Ye Darm	0.6	Draft updated HRT diligence request list.
13	4/21/2020	Diaz, Matthew	0.6	Finalize list of questions on the HRT motion.
13	4/22/2020	Simms, Steven	0.6	Review updated HRT analysis.
13	4/24/2020	Suric, Emil	2.1	Prepare summary re: OTC Naloxone.
13	4/27/2020	Kim, Ye Darm	2.3	Review diligence productions from the Debtors re: financial records.
13	4/28/2020	Bromberg, Brian	2.3	Review HRT documents provided in dataroom.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
13	4/28/2020	Diaz, Matthew	0.7	Review the HRT analysis.
13	4/29/2020	Bromberg, Brian	0.7	Discuss HRT funding motion with team.
13	4/29/2020	Diaz, Matthew	0.6	Review the updated analysis on the HRT funding motion.
13	4/29/2020	Diaz, Matthew	0.6	Review the cash investment motion.
13 Total			131.5	
18	4/20/2020	Diaz, Matthew	0.6	Review the cash transaction report and related follow ups.
18	4/28/2020	Diaz, Matthew	0.6	Review the cash transfer analysis and related next steps re: due diligence.
18	4/28/2020	Greenblatt, Matthew	1.6	Review request list re: cash transfers analysis to identify additions.
18	4/29/2020	Bromberg, Brian	0.5	Participate in call with the team re: historical cash and non-cash transfer diligence workplan.
18	4/29/2020	Greenblatt, Matthew	0.5	Participate in call with the team re: historical cash and non-cash transfer diligence workplan.
18	4/29/2020	Kim, Ye Darm	0.5	Participate in call with the team re: historical cash and non-cash transfer diligence workplan.
18 Total			4.3	
19	4/1/2020	Knechtel, Karl	1.3	Review issues related to document sharing protocol.
19	4/3/2020	Simms, Steven	0.7	Review update of the case.
19	4/6/2020	Kurtz, Emma	0.8	Update index of dataroom to incorporate new documents shared.
19	4/9/2020	Bromberg, Brian	0.9	Incorporate updates to the team's workplan.
19	4/9/2020	Simms, Steven	0.3	Review updated workplan.
19	4/12/2020	Kurtz, Emma	0.7	Prepare updates to Intralinks dataroom index to incorporate recent documents shared.
19	4/15/2020	Simms, Steven	0.4	Correspond with the team re: case updates.
19	4/22/2020	Kurtz, Emma	0.6	Update dataroom index to include additional documents added to share with team.
19	4/27/2020	Kurtz, Emma	0.4	Update dataroom index to include recently uploaded documents to share with team.
19	4/27/2020	Simms, Steven	0.5	Review outstanding case issues.
19 Total			6.6	
21	4/1/2020	Knechtel, Karl	2.3	Review materials in preparation for Committee call.
21	4/3/2020	Kim, Ye Darm	0.9	Participate on call with counsel re: HRT questions and open items.
21	4/3/2020	Knechtel, Karl	0.9	Participate on call with counsel re: HRT questions and open items.
21	4/6/2020	Kim, Ye Darm	1.6	Prepare summary of call with special committee re: ongoing diligence.
21	4/29/2020	Diaz, Matthew	0.6	Participate on call with the Committee's professionals to discuss case next steps.
21 Total			6.3	
24	4/8/2020	Tirabassi, Kathryn	3.4	Begin to prepare March 2020 Fee Statement.
24	4/9/2020	Tirabassi, Kathryn	2.2	Continue to prepare March 2020 Fee Statement.
24	4/9/2020	Tirabassi, Kathryn	2.4	Prepare March 2020 Fee Statement.
24	4/10/2020	Tirabassi, Kathryn	2.7	Prepare March 2020 Fee Statement.
24	4/13/2020	Tirabassi, Kathryn	1.2	Prepare March 2020 Fee Statement.
24	4/15/2020	Tirabassi, Kathryn	0.4	Finalize March 2020 Fee Statement.
24	4/27/2020	Tirabassi, Kathryn	0.2	Finalize February 2020 Fee Statement.
24 Total			12.5	
26	4/20/2020	Bromberg, Brian	2.1	Review Milbank dataroom information provided.
26	4/20/2020	Bromberg, Brian	0.8	Discuss document review on causes of action with Kramer team.
26	4/27/2020	Bromberg, Brian	0.6	Summarize insurance call notes.
26	4/27/2020	Diaz, Matthew	1.9	Review the insurance analysis.
26	4/27/2020	Kim, Ye Darm	2.2	Prepare summary re: insurance programs and causes of action.
26	4/27/2020	Kim, Ye Darm	2.5	Review insurance programs and causes of action.

EXHIBIT C**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020**

Task Category	Date	Professional	Hours	Activity
26 Total			10.1	
28	4/1/2020	Bromberg, Brian	0.8	Review sales price and volume data.
28	4/1/2020	Bromberg, Brian	3.4	Revise diligence question list.
28	4/1/2020	Bromberg, Brian	3.2	Continue to revise diligence question list.
28	4/1/2020	Bromberg, Brian	2.9	Create diligence question template for countries.
28	4/1/2020	Bromberg, Brian	0.5	Participate on call with the Debtors' advisors re: diligence.
28	4/1/2020	Bromberg, Brian	1.7	Continue to create diligence question template for countries.
28	4/1/2020	Diaz, Matthew	1.9	Review the updated diligence request list.
28	4/1/2020	Kim, Ye Darm	0.5	Participate on call with the Debtors' advisors re: diligence.
28	4/1/2020	Kim, Ye Darm	2.7	Prepare country-level diligence questions.
28	4/1/2020	Kurtz, Emma	3.4	Prepare revised country-level financial questions.
28	4/2/2020	Bromberg, Brian	3.1	Incorporate updates to diligence questions.
28	4/2/2020	Bromberg, Brian	3.4	Review the updated diligence questions.
28	4/2/2020	Bromberg, Brian	1.6	Provide comments re: diligence questions.
28	4/2/2020	Bromberg, Brian	2.8	Continue to incorporate updates to diligence questions.
28	4/2/2020	Diaz, Matthew	0.9	Review the updated Germany country list.
28	4/2/2020	Kim, Ye Darm	1.6	Incorporate updates to country-level diligence summaries.
28	4/2/2020	Kim, Ye Darm	2.8	Prepare country-level diligence summaries.
28	4/2/2020	Kurtz, Emma	3.1	Prepare outstanding question summaries for additional IAC country managers.
28	4/2/2020	Kurtz, Emma	2.8	Incorporate updates to outstanding question summaries for IAC country managers.
28	4/2/2020	Kurtz, Emma	0.6	Prepare revisions to IAC business plan review summary.
28	4/3/2020	Bromberg, Brian	0.4	Correspond with Houlihan re: business plan analysis.
28	4/3/2020	Bromberg, Brian	2.4	Review updated IAC information received.
28	4/3/2020	Bromberg, Brian	1.2	Prepare IAC business plan summary.
28	4/3/2020	Diaz, Matthew	2.9	Review IAC financial information.
28	4/3/2020	Kim, Ye Darm	1.1	Incorporate updates to country-level diligence summaries.
28	4/5/2020	Bromberg, Brian	3.4	Respond to question list re: IAC diligence.
28	4/6/2020	Bromberg, Brian	3.1	Create summary of new countries for IAC questions.
28	4/6/2020	Bromberg, Brian	2.1	Prepare updated summaries re: IAC business plan.
28	4/6/2020	Bromberg, Brian	2.8	Prepare questions re: IAC financials.
28	4/6/2020	Bromberg, Brian	2.1	Review updated IAC business plan analysis.
28	4/6/2020	Bromberg, Brian	1.5	Review country product sales.
28	4/6/2020	Bromberg, Brian	1.2	Review IAC financial information.
28	4/6/2020	Diaz, Matthew	0.9	Review the updated IAC questions list.
28	4/6/2020	Kim, Ye Darm	1.8	Incorporate updates to analysis re: IAC financials.
28	4/6/2020	Kurtz, Emma	2.7	Incorporate updates to IAC financials questions list.
28	4/6/2020	Kurtz, Emma	1.8	Review updated IAC financial information.
28	4/6/2020	Kurtz, Emma	3.4	Review IAC financial summaries.
28	4/7/2020	Bromberg, Brian	2.1	Incorporate updates to IAC questions list.
28	4/7/2020	Bromberg, Brian	1.1	Participate in call with Alix re: IAC diligence.
28	4/7/2020	Bromberg, Brian	2.8	Review financial data summary.
28	4/7/2020	Bromberg, Brian	1.4	Finalize IAC questions list.
28	4/7/2020	Bromberg, Brian	2.4	Review updated IAC financial summaries.
28	4/7/2020	Diaz, Matthew	2.7	Review the updated IAC analysis.
28	4/7/2020	Kim, Ye Darm	1.1	Participate in call with Alix re: IAC diligence.
28	4/7/2020	Kim, Ye Darm	3.2	Prepare updated country-level analysis.
28	4/7/2020	Kurtz, Emma	1.2	Prepare analysis re: IAC financial projections.
28	4/7/2020	Kurtz, Emma	2.1	Incorporate further updates to IAC questions list.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
28	4/8/2020	Bromberg, Brian	3.2	Incorporate updates to financial diligence questions.
28	4/8/2020	Bromberg, Brian	2.7	Review updated IAC country-level diligence.
28	4/8/2020	Bromberg, Brian	2.6	Review updated IAC financial information.
28	4/9/2020	Bromberg, Brian	2.9	Finalize diligence questions.
28	4/9/2020	Bromberg, Brian	3.4	Prepare updated analysis re: IAC financials.
28	4/9/2020	Diaz, Matthew	3.2	Conduct a detailed review of the updated IAC summaries.
28	4/9/2020	Diaz, Matthew	2.1	Review the updated IAC diligence list.
28	4/10/2020	Bromberg, Brian	1.3	Review the updated IAC summaries.
28	4/11/2020	Bromberg, Brian	2.4	Review the Debtors' responses to diligence questions.
28	4/11/2020	Bromberg, Brian	2.6	Review comments on IAC business plan summaries.
28	4/11/2020	Bromberg, Brian	1.3	Edit outstanding diligence question list.
28	4/11/2020	Diaz, Matthew	2.9	Conduct a detailed review of the updated IAC summaries.
28	4/11/2020	Diaz, Matthew	0.9	Conduct a detailed review of the updated questions list.
28	4/11/2020	Kurtz, Emma	2.7	Prepare additional analysis re: IAC financials.
28	4/11/2020	Kurtz, Emma	1.4	Continue to prepare additional analysis re: IAC financials.
28	4/12/2020	Bromberg, Brian	1.5	Edit outstanding diligence question list.
28	4/12/2020	Kurtz, Emma	3.1	Prepare further analysis re: IAC financials.
28	4/13/2020	Bromberg, Brian	3.1	Finalize questions list by country.
28	4/13/2020	Bromberg, Brian	2.9	Revise diligence questions for the Debtors.
28	4/13/2020	Bromberg, Brian	3.4	Conduct a detailed review of IAC financial summaries.
28	4/13/2020	Bromberg, Brian	2.7	Review updated IAC financial information received.
28	4/13/2020	Diaz, Matthew	1.2	Review the updated question and country list.
28	4/13/2020	Diaz, Matthew	2.6	Conduct a detailed review of the updated IAC summaries.
28	4/13/2020	Kim, Ye Darm	1.9	Incorporate updates to diligence list.
28	4/13/2020	Kim, Ye Darm	2.6	Incorporate updates to IAC financial summaries.
28	4/13/2020	Kurtz, Emma	2.6	Review comments to IAC summaries.
28	4/13/2020	Kurtz, Emma	2.8	Prepare additional revisions to country-level outstanding diligence questions lists.
28	4/13/2020	Kurtz, Emma	0.6	Review revised outstanding diligence request list.
28	4/13/2020	Kurtz, Emma	3.1	Incorporate updates to IAC summaries.
28	4/14/2020	Bromberg, Brian	2.8	Incorporate updates to IAC summaries.
28	4/14/2020	Bromberg, Brian	2.6	Continue to incorporate updates to IAC summaries.
28	4/14/2020	Bromberg, Brian	3.1	Prepare analysis re: IAC financials.
28	4/14/2020	Bromberg, Brian	2.4	Continue to prepare analysis re: IAC financials.
28	4/14/2020	Diaz, Matthew	0.9	Review the updated IAC question list.
28	4/14/2020	Kim, Ye Darm	2.3	Review updated IAC financial summaries.
28	4/14/2020	Kim, Ye Darm	1.8	Incorporate updates to IAC financial summaries.
28	4/14/2020	Kurtz, Emma	3.3	Prepare additional analyses re: IAC financials.
28	4/14/2020	Kurtz, Emma	3.1	Continue to prepare additional analyses re: IAC financials.
28	4/14/2020	Kurtz, Emma	2.2	Prepare updated IAC summaries.
28	4/15/2020	Bromberg, Brian	2.8	Review updated IAC summaries.
28	4/15/2020	Bromberg, Brian	1.1	Prepare response to the Debtors re: diligence.
28	4/15/2020	Bromberg, Brian	3.4	Review new information received from the Debtors.
28	4/15/2020	Bromberg, Brian	2.9	Prepare comments re: updated IAC summaries.
28	4/15/2020	Diaz, Matthew	2.1	Review the updated IAC analysis.
28	4/15/2020	Kim, Ye Darm	0.5	Review updated IAC summaries.
28	4/15/2020	Kurtz, Emma	3.4	Prepare additional analysis re: IAC financial projections.
28	4/15/2020	Kurtz, Emma	2.6	Continue to prepare additional analysis re: IAC financial projections.
28	4/15/2020	Kurtz, Emma	2.2	Prepare summaries re: IAC financial projections.
28	4/16/2020	Bromberg, Brian	3.3	Edit IAC summaries.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Task Category	Date	Professional	Hours	Activity
28	4/16/2020	Bromberg, Brian	0.5	Review comparable company analysis.
28	4/16/2020	Bromberg, Brian	1.8	Review analysis re: IAC financial projections.
28	4/16/2020	Kim, Ye Darm	2.1	Incorporate updates to IAC financial summaries.
28	4/16/2020	Kurtz, Emma	2.8	Prepare additional analysis re: IAC financial projections.
28	4/16/2020	Kurtz, Emma	2.6	Continue to prepare additional analysis re: IAC financial projections.
28	4/17/2020	Bromberg, Brian	1.4	Review comparable company analysis.
28	4/17/2020	Diaz, Matthew	1.1	Review the updated IAC analysis.
28	4/17/2020	Kim, Ye Darm	2.6	Incorporate comments to IAC summaries.
28	4/17/2020	Kurtz, Emma	1.1	Incorporate updates to IAC analysis.
28	4/18/2020	Bromberg, Brian	3.2	Edit IAC summaries.
28	4/19/2020	Bromberg, Brian	2.8	Review updated analysis re: IAC financial projections.
28	4/19/2020	Bromberg, Brian	3.2	Prepare detailed comments re: updated IAC summaries.
28	4/19/2020	Kim, Ye Darm	1.9	Incorporate updates to IAC analysis.
28	4/19/2020	Kurtz, Emma	2.3	Incorporate updates to IAC financial projection analysis.
28	4/19/2020	Kurtz, Emma	1.4	Incorporate comments to IAC summaries.
28	4/20/2020	Bromberg, Brian	3.1	Prepare additional IAC summaries.
28	4/20/2020	Bromberg, Brian	3.4	Review IAC financial projection analysis.
28	4/20/2020	Bromberg, Brian	1.6	Review latest version of IAC summaries.
28	4/20/2020	Kim, Ye Darm	2.6	Incorporate updates to analysis re: IAC financial projections.
28	4/20/2020	Kim, Ye Darm	2.9	Incorporate comments to IAC financial summaries.
28	4/20/2020	Kurtz, Emma	1.4	Review outstanding diligence requests.
28	4/20/2020	Kurtz, Emma	3.2	Incorporate updates to IAC financial summaries.
28	4/20/2020	Kurtz, Emma	1.8	Prepare additional analysis re: IAC financials.
28	4/21/2020	Bromberg, Brian	2.3	Prepare comments re: IAC summaries.
28	4/21/2020	Bromberg, Brian	0.7	Participate on call with the Debtors' advisors re: diligence.
28	4/21/2020	Bromberg, Brian	1.4	Review analysis prepared by Houlihan.
28	4/21/2020	Bromberg, Brian	2.6	Review updated IAC analysis.
28	4/21/2020	Bromberg, Brian	1.7	Prepare comments re: updated IAC analysis.
28	4/21/2020	Bromberg, Brian	1.1	Prepare additional diligence questions re: IACs.
28	4/21/2020	Diaz, Matthew	1.7	Review the updated IAC analysis.
28	4/21/2020	Kim, Ye Darm	2.8	Review IAC financial analysis.
28	4/21/2020	Kurtz, Emma	2.3	Prepare analysis re: comparable companies.
28	4/21/2020	Kurtz, Emma	2.6	Incorporate updates to IAC business plan analysis.
28	4/22/2020	Bromberg, Brian	1.4	Review updated IAC documents provided.
28	4/22/2020	Bromberg, Brian	0.8	Discuss diligence with IAC advisors.
28	4/22/2020	Diaz, Matthew	1.8	Review the updated IAC summaries.
28	4/22/2020	Kim, Ye Darm	1.3	Review diligence responses re: IAC business plan diligence requests.
28	4/22/2020	Kurtz, Emma	0.3	Prepare additional outstanding diligence questions.
28	4/23/2020	Bromberg, Brian	0.5	Prepare video conferencing software for meeting with non-consenting states re: information sharing.
28	4/24/2020	Bromberg, Brian	0.9	Follow up on outstanding items from non-consenting states call.
28	4/24/2020	Bromberg, Brian	2.0	Participate in call with non-consenting states re: information sharing and diligence update.
28	4/24/2020	Bromberg, Brian	2.4	Review February financial report summary.
28	4/24/2020	Bromberg, Brian	3.1	Prepare for call with non-consenting states re: information sharing and diligence update.
28	4/24/2020	Diaz, Matthew	2.9	Review materials in preparation for the call with the non consenting states.
28	4/24/2020	Diaz, Matthew	2.0	Participate in call with non-consenting states re: information sharing and diligence update.

EXHIBIT C**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****DETAIL OF TIME ENTRIES****FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020**

Task Category	Date	Professional	Hours	Activity
28	4/24/2020	Diaz, Matthew	0.5	Participate on call with Kramer and Houlihan to prepare for the call with the non consenting states.
28	4/24/2020	Kim, Ye Darm	2.0	Participate in call with non-consenting states re: information sharing and diligence update.
28	4/24/2020	Kim, Ye Darm	0.5	Participate on call with Kramer and Houlihan to prepare for the call with the non consenting states.
28	4/27/2020	Bromberg, Brian	0.9	Coordinate diligence questions with advisors.
28	4/27/2020	Diaz, Matthew	0.8	Review due diligence items open items.
28	4/28/2020	Bromberg, Brian	0.5	Review data files in preparation for call with the Debtors.
28	4/28/2020	Diaz, Matthew	1.7	Review the updated business plan.
28	4/28/2020	Diaz, Matthew	2.1	Review the updated IAC analysis.
28	4/29/2020	Bromberg, Brian	2.6	Review updated IAC documents.
28	4/29/2020	Bromberg, Brian	2.1	Continue to review updated IAC documents.
28	4/29/2020	Bromberg, Brian	0.5	Participate on call with counsel re: information sharing protocol with the non-consenting states.
28	4/29/2020	Bromberg, Brian	3.1	Review updated IAC financial analysis.
28	4/29/2020	Bromberg, Brian	1.7	Continue to review updated IAC financial analysis.
28	4/29/2020	Kurtz, Emma	3.4	Prepare additional analysis re: IAC financials.
28	4/29/2020	Kurtz, Emma	3.2	Continue to prepare additional analysis re: IAC financials.
28	4/29/2020	Kurtz, Emma	2.9	Prepare additional summaries re: IAC financials.
28	4/29/2020	Kurtz, Emma	1.1	Prepare outstanding question list.
28	4/30/2020	Bromberg, Brian	3.3	Review updated IAC financials.
28	4/30/2020	Bromberg, Brian	0.5	Participate on call with Houlihan re: updated IAC financials.
28	4/30/2020	Bromberg, Brian	1.3	Continue to review updated IAC financials.
28	4/30/2020	Bromberg, Brian	0.7	Participate on call with IAC professionals re: updated financial information.
28	4/30/2020	Diaz, Matthew	0.7	Participate on call with IAC professionals re: updated financial information.
28	4/30/2020	Kim, Ye Darm	0.5	Participate on call with Houlihan re: updated IAC financials.
28	4/30/2020	Kim, Ye Darm	0.7	Participate on call with IAC professionals re: updated financial information.
28	4/30/2020	Kim, Ye Darm	0.4	Review updated IAC materials in preparation for calls.
28	4/30/2020	Kurtz, Emma	0.5	Participate on call with Houlihan re: updated IAC financials.
28	4/30/2020	Kurtz, Emma	0.7	Participate on call with IAC professionals re: updated financial information.
28	4/30/2020	Kurtz, Emma	2.4	Prepare additional analysis re: IAC financials.
28	4/30/2020	Kurtz, Emma	1.7	Continue to prepare additional analysis re: IAC financials.
28 Total			349.5	
Grand Total			594.9	

EXHIBIT D**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649****SUMMARY OF EXPENSES****FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020**

Expense Type	Amount
Transportation	\$ 24.59
Working Meals ¹	320.00
Other	1,387.69
Grand Total	\$ 1,732.28

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD APRIL 1, 2020 TO APRIL 30, 2020

Date	Professional	Expense Type	Expense Detail	Amount
2/20/2020	Bromberg, Brian	Transportation	Taxi home from the office after working late on the case.	\$ 24.59
		Transportation Total		\$ 24.59
1/29/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/30/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
1/30/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
2/13/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/17/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/18/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/18/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
2/19/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
2/20/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
2/24/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/25/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/26/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
2/27/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
3/3/2020	Bromberg, Brian	Working Meals	Dinner while working late in the office on the case.	20.00
3/3/2020	Kim, Ye Darm	Working Meals	Dinner while working late in the office on the case.	20.00
3/3/2020	Kurtz, Emma	Working Meals	Dinner while working late in the office on the case.	20.00
		Working Meals Total		\$ 320.00
4/1/2020	Rosini, Andrew	Other	Refinitiv data purchase.	81.52
4/30/2020	Butterfield, Linda	Other	Access to Lexis Nexis for research regarding the HRT motion.	193.64
4/30/2020	Harsha, Adam	Other	Access to Lexis Nexis for research regarding the HRT motion.	535.21
4/30/2020	Causton, Daniel	Other	Access to Lexis Nexis for research regarding the HRT motion.	577.32
		Other Total		\$ 1,387.69
		Grand Total		\$ 1,732.28

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.